HER2-Negative Breast Cancer Market Forecast To Reach $25.41 Billion By 2030: Key Trends Explained

HER2-Negative Breast Cancer Market Report

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

HER2-Negative Breast Cancer Market CAGR Outlook And Future Development

The her2-negative breast cancer market size has experienced robust growth in recent years. Forecasts show it will climb from $17.57 billion in 2025 to $18.95 billion in 2026, with a compound annual growth rate (CAGR) of 7.9%. Attributing factors for this growth in earlier periods include an uptick in breast cancer screening rates, heightened awareness regarding hormone receptor-positive cancers, an increase in oncology treatment center availability, the presence of well-established chemotherapy protocols, and a surge in clinical oncology research.

The her2-negative breast cancer market size is anticipated to experience substantial growth in the upcoming years. It is forecasted to reach $25.41 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.6%. This projected growth within the forecast period can be attributed to several factors, including the increasing demand for personalized oncology treatments, the rising adoption of genomic-driven therapies, the expansion of immunotherapy pipelines, a growing focus on improving progression-free survival, and increasing investment in oncology drug development. Key trends identified for the forecast period encompass the increasing adoption of personalized hormone therapy regimens, the growing use of cdk4/6 inhibitors, the expansion of genomic testing for treatment selection, the rising integration of immunotherapy in advanced stages, and an enhanced focus on combination treatment protocols.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=50962770&type=smp&name=HER2-Negative%20Breast%20Cancer%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

HER2-Negative Breast Cancer Market Growth Catalysts And Demand Drivers

The increasing occurrence of breast cancer is anticipated to drive the expansion of the HER2-negative breast cancer market. This condition is defined by the unchecked proliferation of irregular cells within breast tissue, typically starting in the ducts or lobules. The growing number of breast cancer cases can be linked to multiple elements, such as heightened awareness and better screening techniques, which facilitate earlier and more regular diagnoses. HER2-Negative Breast Cancer is vital for progressing breast cancer research by offering understandings of unique tumor biology and therapeutic approaches, thus aiding in the creation of more focused treatments for patients. For example, the American Cancer Society, a US-based professional organization company, forecasts that in 2025, the United States will likely record around 316,950 new cases of invasive breast cancer in women and 2,800 cases in men, in addition to an estimated 59,080 cases of ductal carcinoma in situ (DCIS) diagnosed in women. Consequently, the escalating frequency of breast cancer cases is fueling the expansion of the HER2-negative breast cancer market.

HER2-Negative Breast Cancer Market Breakdown By Product Type And Application

The her2-negative breast cancer market covered in this report is segmented –

1) By Treatment Type: Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy

2) By Cancer Stage: Early Stage, Locally Advanced Stage, Metastatic Stage

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Chemotherapy: Anthracyclines, Taxanes, Platinum-Based Chemotherapy, Alkylating Agents, Antimetabolites

2) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Degraders (SERDs)

3) By Targeted Therapy: CDK4/6 Inhibitors, PI3K Inhibitors, PARP Inhibitors

4) By Immunotherapy: Immune Checkpoint Inhibitors, Tumor-Infiltrating Lymphocyte (TIL) Therapy

HER2-Negative Breast Cancer Market Industry Trends: What’s Reshaping Demand?

Leading firms within the HER2-negative breast cancer sector are concentrating on obtaining regulatory clearances to launch novel therapies, broaden their range of products, and strengthen their position in the market. Such approvals signify the formal permission issued by governmental bodies, enabling companies to commercialize and supply medications or treatments once specific safety, effectiveness, and quality criteria have been satisfied. As an illustration, in October 2024, Genentech Inc., an American biotechnology company, secured FDA approval for Itovebi (inavolisib), which serves as a targeted therapy for advanced hormone receptor-positive (HR+), HER2-negative breast cancer characterized by a PIK3CA mutation. This clearance permits Itovebi’s use alongside palbociclib and fulvestrant, substantially enhancing progression-free survival rates for patients when contrasted with conventional therapies. This novel treatment approach offers a crucial alternative for individuals with restricted therapeutic options, underscoring the necessity of biomarker testing to pinpoint those most likely to gain from this particular treatment.

HER2-Negative Breast Cancer Market Company Landscape And Competitive Strategy

Major companies operating in the her2-negative breast cancer market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hansoh Pharmaceutical Co. Ltd., BeiGene Ltd., Chipscreen Biosciences Ltd., F. Hoffmann-La Roche Ltd, PharmAbcine Inc., Adagene Inc., H3 Biomedicine Inc., Radius Health Inc., Zenith Epigenetics Ltd.

View The Full HER2-Negative Breast Cancer Market Report:

https://thebusinessresearchcompany.com/report/her2-negative-breast-cancer-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

HER2-Negative Breast Cancer Market Geographic Landscape: Which Region Leads Industry Growth?

North America was the largest region in the HER2-negative breast cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the her2-negative breast cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model